Floatz logo

23 assets in Fabry Disease

Therapeutic assets addressing Fabry Disease, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Recombinant Alpha-Galactosidase A
Fabry Disease
ShireP4A (84)
Agalsidase Beta
Fabry Disease
SanofiP4A (83)
Migalastat
Fabry Disease
Amicus TherapeuticsP3BBB (79)
Pegunigalsidase Alfa
Fabry Disease
Chiesi ItaliaP3BBB (79)
Fexofenadine
Fabry Disease
SanofiP4BB (69)
Loratadine
Fabry Disease
SanofiP4BB (69)
Montelukast
Fabry Disease
SanofiP4BB (69)
Lucerastat
Fabry Disease
Idorsia Pharmaceuticals Ltd.P3BB (67)
Dexasone
Fabry Disease
SanofiP4BB (66)
Cetirizine
Fabry Disease
SanofiP4BB (64)
Diphenhydramine
Fabry Disease
SanofiP4B (62)
Venglustat
Fabry Disease
SanofiP3B (61)
AL-01211
Fabry Disease
AceLink Therapeutics, Inc.P2CCC (53)
Dapagliflozin
Fabry Disease
Albina Nowak, MDP2CCC (53)
Isaralgagene Civaparvovec
Fabry Disease
Sangamo TherapeuticsP1/2CCC (50)
GC1134A
Fabry Disease
GC Biopharma CorpP1/2CCC (48)
HM15421
Fabry Disease
GC Biopharma CorpP1/2CCC (48)
Amt-191
Fabry Disease
UniQure Biopharma B.V.P1/2CC (47)
Apabetalone
Fabry Disease
Resverlogix CorpP1/2CC (47)
Duvalgagene Otiparvovec
Fabry Disease
4D Molecular TherapeuticsP1/2CC (47)
exg110
Fabry Disease
Guangzhou Jiayin Biotech LtdP1/2CC (47)
Agalsidase Beta From Biosidus /Kg
Fabry Disease
Bio Sidus SAP1CC (46)
Bbm-F101
Fabry Disease
Children's Hospital of Fudan UniversityEarly P1C (39)